These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35753940)

  • 1. Bismuth chelation for targeted alpha therapy: Current state of the art.
    Franchi S; Di Marco V; Tosato M
    Nucl Med Biol; 2022; 114-115():168-188. PubMed ID: 35753940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes.
    Wilson JJ; Ferrier M; Radchenko V; Maassen JR; Engle JW; Batista ER; Martin RL; Nortier FM; Fassbender ME; John KD; Birnbaum ER
    Nucl Med Biol; 2015 May; 42(5):428-438. PubMed ID: 25684650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancements in cancer therapy with alpha-emitters: a review.
    Imam SK
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):271-8. PubMed ID: 11516878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuning the Kinetic Inertness of Bi
    Fiszbein DJ; Brown V; Thiele NA; Woods JJ; Wharton L; MacMillan SN; Radchenko V; Ramogida CF; Wilson JJ
    Inorg Chem; 2021 Jun; 60(12):9199-9211. PubMed ID: 34102841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted alpha therapy: part I.
    Elgqvist J
    Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boosting Bismuth(III) Complexation for Targeted α-Therapy (TAT) Applications with the Mesocyclic Chelating Agent AAZTA.
    Horváth D; Vágner A; Szikra D; Trencsényi G; Demitri N; Guidolin N; Maiocchi A; Ghiani S; Travagin F; Giovenzana GB; Baranyai Z
    Angew Chem Int Ed Engl; 2022 Oct; 61(43):e202207120. PubMed ID: 36073561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing
    Yang H; Wilson JJ; Orvig C; Li Y; Wilbur DS; Ramogida CF; Radchenko V; Schaffer P
    J Nucl Med; 2022 Jan; 63(1):5-13. PubMed ID: 34503958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer.
    Allen BJ
    Australas Radiol; 1999 Nov; 43(4):480-6. PubMed ID: 10901964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.
    Kozempel J; Mokhodoeva O; Vlk M
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29510568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.
    Zalutsky MR; Bigner DD
    Acta Oncol; 1996; 35(3):373-9. PubMed ID: 8679269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.
    Morgenstern A; Bruchertseifer F; Apostolidis C
    Curr Radiopharm; 2012 Jul; 5(3):221-7. PubMed ID: 22642390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunoconjugates for targeted alpha therapy of malignant melanoma.
    Abbas Rizvi SM; Sarkar S; Goozee G; Allen BJ
    Melanoma Res; 2000 Jun; 10(3):281-9. PubMed ID: 10890383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy with α-particle-emitting radionuclides.
    Seidl C
    Immunotherapy; 2014; 6(4):431-58. PubMed ID: 24815783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation.
    Wulbrand C; Seidl C; Gaertner FC; Bruchertseifer F; Morgenstern A; Essler M; Senekowitsch-Schmidtke R
    PLoS One; 2013; 8(5):e64730. PubMed ID: 23724085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Achievements about Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents.
    Farzipour S; Shaghaghi Z; Abbasi S; Albooyeh H; Alvandi M
    Anticancer Agents Med Chem; 2022; 22(8):1496-1510. PubMed ID: 34315393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics.
    Huclier-Markai S; Alliot C; Varmenot N; Cutler CS; Barbet J
    Curr Top Med Chem; 2012; 12(23):2642-54. PubMed ID: 23339760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
    Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
    Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Overview of Targeted Alpha Therapy with
    Morgenstern A; Apostolidis C; Kratochwil C; Sathekge M; Krolicki L; Bruchertseifer F
    Curr Radiopharm; 2018; 11(3):200-208. PubMed ID: 29732998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
    Lee D; Li M; Bednarz B; Schultz MK
    Radiat Res; 2018 Sep; 190(3):236-247. PubMed ID: 29944461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205/Bismuth-206.
    Abbas Rizvi SM; Song EY; Raja C; Beretov J; Morgenstern A; Apostolidis C; Russell PJ; Kearsley JH; Abbas K; Allen BJ
    Cancer Biol Ther; 2008 Oct; 7(10):1547-54. PubMed ID: 18708762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.